University of Patras
Σχεδιασμός και ανάπτυξη νέων συνθετικών αναλόγων της ωκυτοκίνης με ανταγωνιστική δράση: σχέσεις δομής - βιολογικής δραστικότητας
Abstract
dc:descriptionIn the present study we present the synthesis and pharmacological investigation of twenty seven newly synthesized oxytocin analogues. Basic modification at positions 7, 8 and 9 (introduction of α,α-dialkyl amino acid, α-aminoisobutyric acid [Aib] or the unnatural imino acid D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [D-Tic] or tert-butyl-glycine [(But)Gly]) was combined with D-Cys6/Pen6, D-Tyr(Et)2, and D-Nal(1)2, Mpa1/Pen1 modifications and their various combinations.The new analogues (following table) were synthesized by Fmoc solid phase methodology utilizing a 2-chlorotrityl chloride resin as solid support bearing a Rink-Bernatowitz linker to provide the peptidic amide and diisopropylcarbodiimide/1-hydroxy-benzotriazol (DIC/HOBt) as coupling agent. The cyclization was performed in DMSO/H2O (2:8, v/v) for 24-36h Final purification was achieved by preparative HPLC (Pharmacia LKB-2250) on reversed-phase support C-18 with a linear gradient from 25 to 75% acetonitrile (0.1% TFA) for 35 min. The appropriate fractions were pooled and lyophilized. Electron-spray MS were in agreement with the expected results.The analogues were tested for their potency in two pharmacological tests, i.e. uterotonic in vitro test in the absence of magnesium ions on an isolated strip of rat uterus and in the pressοr test on phenoxybenzamine treated male rats. Parallel determination of binding affinity of the analogues to cloned human oxytocin recep-tors on HEK cell membranes using tritiated oxytocin from NEN Life Science, Boston, MA, USA was performed. We obtained a satisfactory number of quite potent and selective (as it concerns the binding with the vasopresor receptor V1a) oxytocin antagonists. Ten of these analogues showed higher antagonistic affinity than Atosiban (pA2=8.29) and they were completely inactive as far as it concerns the rat pressor test. Three of them (MOPACIN I, II and III) are under patent procedure. On the other hand, as it concerns the binding affinity and the biological evaluation, we observed a paradox phenomenon. Despite the high anta-gonistic potencies the affinity to the receptor was lower than oxytocin. This may be attri-buted to the species difference.Furthermore, some of the analogues were tested as far as it concerns their ability to in-crease or decrease the growth of MCF-7 breast cancer cells. The results indicate the ability of some analogues to decrease the growth of the MCF-7 breast cancer cells, but these re-sults need further investigation due to extract safe conclusions.Finally, the results from the presence study may aid in the design of novel and selective antagonists of oxytocin with pharmacological/pharmaceutical use. Furthermore, the evi-dence that some analogues have the ability to decrease the growth of MCF-7 cells, may find future applications in the radioimaging of different neoplasms, as wel as in their therapy, using oxytocin analogues that conserve high oxytocin receptor affinity as either radiotracers or chemiotherapeutic vectors.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2004
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fragiadaki, Maria
- Φραγκιαδάκη, Μαρία
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34082